Randolph Company’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-202,207
Closed -$16.2M 41
2020
Q1
$16.2M Buy
+202,207
New +$20.9M 3.22% 16
2017
Q2
Sell
-234,025
Closed -$23M 38
2017
Q1
$23M Sell
234,025
-125
-0.1% -$11.9K 4.39% 5
2016
Q4
$21.5M Buy
234,150
+150
+0.1% +$12.9K 4.41% 5
2016
Q3
$19.8M Sell
234,000
-100
-0% -$8.4K 4.99% 7
2016
Q2
$19.1M Hold
234,100
4.9% 5
2016
Q1
$16.7M Buy
234,100
+29,725
+15% +$1.99M 3.73% 12
2015
Q4
$14.5M Sell
204,375
-25
-0% -$1.68K 3.7% 17
2015
Q3
$12.6M Sell
204,400
-1
-0% -$70 3.01% 19
2015
Q2
$14.8M Buy
204,401
+1
+0% +$74 3.35% 19
2015
Q1
$15.7M Sell
204,400
-9,000
-4% -$645K 3.41% 19
2014
Q4
$14.3M Sell
213,400
-13,600
-6% -$858K 2.77% 20
2014
Q3
$13.8M Hold
227,000
2.85% 21
2014
Q2
$13.3M Hold
227,000
2.88% 20
2014
Q1
$13.1M Buy
227,000
+9,100
+4% +$488K 2.84% 21
2013
Q4
$11.7M Buy
+217,900
New +$12.9M 2.31% 21

Other funds holding DGX

Randolph Company's DGX Position: Q2 2020 in Review

Randolph Company sold out of Quest Diagnostics (DGX) in Q2 2020, closing a stake of 202,207 shares — an estimated $16.2M sold.

Randolph Company first reported a position in DGX in Q4 2013 and held it in 15 quarters. The position peaked at $23M in Q1 2017. 749 funds tracked by Wall St. Rank hold DGX as of Q2 2020.

  • Randolph Company reported no remaining Quest Diagnostics position as of Q2 2020 after selling out during the quarter.
  • Randolph Company sold 202,207 Quest Diagnostics shares in Q2 2020, an estimated $16.2M.
  • Randolph Company first reported a position in Quest Diagnostics in Q4 2013 and held it in 15 quarters.
  • Randolph Company's Quest Diagnostics position peaked at $23M in Q1 2017.
  • 749 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2020.

Based on Randolph Company's 13F filing for Q2 2020, filed 22 Jul 2020.